| pubmed-article:2577475 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2577475 | lifeskim:mentions | umls-concept:C0019682 | lld:lifeskim |
| pubmed-article:2577475 | lifeskim:mentions | umls-concept:C0019699 | lld:lifeskim |
| pubmed-article:2577475 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2577475 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2577475 | lifeskim:mentions | umls-concept:C0021745 | lld:lifeskim |
| pubmed-article:2577475 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:2577475 | lifeskim:mentions | umls-concept:C0033268 | lld:lifeskim |
| pubmed-article:2577475 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:2577475 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2577475 | pubmed:dateCreated | 1991-10-7 | lld:pubmed |
| pubmed-article:2577475 | pubmed:abstractText | We studied gamma interferon (IFN) production in vitro by lymphocytes from 5 patients with AIDS and 2 with advanced AIDS-related complex (ARC) before and during treatment with r-alpha 2a IFN at low doses, for up to 12 months. Patients were divided in responders (three) and non responders according to clinical data after six months of treatment. No immunological parameter was predictive of the clinical results. We found that subpopulations of T lymphocytes and lymphoproliferative response were not significantly modified in responders, while severely decreased in non responder patients. In 5/7 cases we observed a small but significant increase of gamma IFN production after six months of therapy, which rose to normal values after 12 months in responders. | lld:pubmed |
| pubmed-article:2577475 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2577475 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2577475 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2577475 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2577475 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2577475 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2577475 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2577475 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2577475 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2577475 | pubmed:issn | 0021-2547 | lld:pubmed |
| pubmed-article:2577475 | pubmed:author | pubmed-author:AiutiFF | lld:pubmed |
| pubmed-article:2577475 | pubmed:author | pubmed-author:DianzaniFF | lld:pubmed |
| pubmed-article:2577475 | pubmed:author | pubmed-author:CherchiMM | lld:pubmed |
| pubmed-article:2577475 | pubmed:author | pubmed-author:PaganelliRR | lld:pubmed |
| pubmed-article:2577475 | pubmed:author | pubmed-author:CapobianchiM... | lld:pubmed |
| pubmed-article:2577475 | pubmed:author | pubmed-author:Di MarcoPP | lld:pubmed |
| pubmed-article:2577475 | pubmed:author | pubmed-author:MezzaromaII | lld:pubmed |
| pubmed-article:2577475 | pubmed:author | pubmed-author:D'OffiziG PGP | lld:pubmed |
| pubmed-article:2577475 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2577475 | pubmed:volume | 68 | lld:pubmed |
| pubmed-article:2577475 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2577475 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2577475 | pubmed:pagination | 67-71 | lld:pubmed |
| pubmed-article:2577475 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:meshHeading | pubmed-meshheading:2577475-... | lld:pubmed |
| pubmed-article:2577475 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2577475 | pubmed:articleTitle | Alpha interferon treatment in HIV infected patients restores gamma interferon production in vitro. | lld:pubmed |
| pubmed-article:2577475 | pubmed:affiliation | Cattedra di Allergologia e Immunologia Clinica, Università La Sapienza, Roma. | lld:pubmed |
| pubmed-article:2577475 | pubmed:publicationType | Journal Article | lld:pubmed |
